公司概述
Cencora, Inc. functions as a pivotal entity within the healthcare landscape, primarily engaged in the sourcing and distribution of pharmaceutical products across the United States and international markets. Operating within the Healthcare sector and specifically the Medical Distribution industry, the company serves as a critical logistical bridge connecting manufacturers with pharmacies, hospitals, and other healthcare providers. The enterprise commands a substantial market capitalization of $62.73B, supported by annual revenue reaching $325.78B and an extensive workforce of 47,000 employees. These valuation and revenue figures underscore the company's massive scale and its entrenched position as a dominant player in the pharmaceutical supply chain, reflecting the immense volume of goods it handles and the systemic importance it holds within the broader healthcare infrastructure.
财务健康
Cencora, Inc. reported a Total Revenue of $325.78B over the trailing twelve months, generating Net Income of $1.63B and an EBITDA of $4.96B. The significant disparity between the $325.78B in revenue and the $1.63B in net income highlights a highly leveraged cost structure where operating expenses, including logistics, warehousing, and distribution costs, consume the vast majority of top-line sales. Despite the low net income relative to revenue, the company maintains robust Free Cash Flow of $3.46B, which provides significant financial flexibility for operational investments, debt servicing, and potential strategic initiatives without relying solely on external financing. The company's margin profile is characterized by a Gross Margin of 3.6%, an Operating Margin of 1.2%, and a Profit Margin of 0.5%, all of which are typical for a low-margin, high-volume distribution business where efficiency in the supply chain is the primary driver of profitability rather than product markup. In terms of liquidity and leverage, the company holds $1.75B in cash against $9.91B in total debt, resulting in a Debt to Equity ratio of 472.58, which indicates a highly leveraged balance sheet reliant on consistent cash flow generation to meet obligations. The Current Ratio stands at 0.92, suggesting that the company's current liabilities slightly exceed its current assets, a condition common in capital-intensive distribution models but requiring careful working capital management. Return on Equity is reported at 133.5% while Return on Assets is 3.3%, metrics that reveal management's effectiveness in utilizing shareholder capital and asset base respectively, with the exceptionally high ROE driven by the company's substantial debt load amplifying returns on equity.
估值评估
The stock carries a Trailing P/E Ratio of 38.76 and a Forward P/E of 16.46, a pronounced difference that implies the market expects a significant expansion in earnings per share to justify the current high valuation multiple relative to future projections. The Price to Book ratio is 32.87, indicating that the market values the company at a substantial premium over its book value, likely reflecting the intangible value of its distribution network and market position rather than traditional asset backing. Alternative valuation metrics show a Price to Sales ratio of 0.19 and an EV/EBITDA of 14.32, suggesting that while the earnings multiple is high, the valuation relative to sales and enterprise value appears more moderate when accounting for the company's massive revenue base and EBITDA generation. The 52-week price range spans from a low of $269.37 to a high of $377.54, providing a clear view of the recent price volatility and historical trading bounds for the asset. The Beta value is 0.72, which indicates that the stock's price volatility is lower than the broader market, suggesting it may act as a relative defensive holding within the healthcare sector during periods of market turbulence.
Growth & Income
Revenue growth for the trailing twelve months stands at 5.5%, while earnings growth is recorded at 14.8%, demonstrating that earnings are growing at a significantly faster pace than revenue, which often points to improving operational efficiencies or favorable mix shifts in the product portfolio. As a dividend payer, the company offers a Dividend Yield of 0.7% with a Payout Ratio of 27.0%, a conservative payout level that suggests the dividend is highly sustainable given the company's strong free cash flow generation and low payout percentage relative to earnings. This conservative approach allows the company to retain a majority of its earnings for reinvestment into distribution capabilities or debt reduction rather than distributing them entirely to shareholders. Overall, the growth and income profile reflects a mature, high-volume distribution business delivering steady, albeit modest, income returns supported by accelerating earnings growth driven by internal operational leverage.